Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 13Hodgkin Disease 11Lymphoma, Non-Hodgkin 10Lymphoma, Large B-Cell, Diffuse 10Lymphoma, Follicular 10Lymphoma, Mantle-Cell 9Lymphoma 9Leukemia, Lymphocytic, Chronic, B-Cell 7Recurrence 6Lymphoma, B-Cell 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, B-Cell, Marginal Zone 3Leukemia 3Immune System Diseases 3Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Neoplasms, Plasma Cell 2Neoplasms 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Extranodal NK-T-Cell 2Leukemia, Myeloid, Acute 2Burkitt Lymphoma 2Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Squamous Cell Carcinoma of Head and Neck 1Sezary Syndrome 1Sarcoma 1Proteostasis Deficiencies 1

Interventions

venetoclax 1pomalidomide 1ixazomib 1daratumumab 1Dexamethasone 1Calcium Dobesilate 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Proteostasis Deficiencies × Bendamustine Hydrochloride × Clear all
NCT05451771 2025-07-08

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

Columbia University

Phase 1/2 Recruiting
53 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Proteostasis Deficiencies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡